TOKYO, May 19 (Pulse News Wire) – Adr120s,inc. (3750.T) announced today that its subsidiary, ADR Therapeutics Co., Ltd., has entered into a joint research agreement with Northern Farm to explore the application of Neocella in improving uterine health for racehorses suffering from persistent mating-induced endometritis (PMIE) and other inflammatory conditions.
The collaboration, set to begin, aims to accumulate case studies during the 2026 breeding season and conduct detailed observations and analyses. Key areas of focus include evaluating the effectiveness of cell-derived components in reproductive health and collecting medical evidence for Neocella's potential applications overseas. Northern Farm, established in January 1994, specializes in the production, training, and breeding of racehorses.
The joint venture complements ongoing foundational research with Tokyo Medical University aimed at understanding Neocella’s biological functions and mechanisms of action. In the coming months, ADR120S plans to advance practical research in the field of equine reproduction through this partnership while continuing scientific analysis with Tokyo Medical University. Detailed data and results from the study will be reviewed post-breeding season, with potential for further public disclosure.
The company stated that the impact of this contract on its performance is currently minor but will promptly disclose any significant developments moving forward.
🟢 Confidence: High AI-translated content.